SIGALMED Leipzig

At SIGALMED Leipzig, researchers are advancing therapies aimed at weight reduction for adults identified with overweight or obesity without diabetes, testing the effectiveness of new peptide agents such as olatorepatide to support healthier body composition.

• Novel peptide therapies for weight management
• Integration of lifestyle counseling with pharmacologic treatment
• Safety and efficacy profiling in non‑diabetic obesity

The site, located in Naunhof, Germany, conducts these studies with a dedicated team of two investigators, emphasizing patient‑centered outcomes and rigorous safety monitoring.

In the realm of infectious disease, SIGALMED Leipzig is evaluating a combination vaccine that merges a recombinant spike protein for SARS‑CoV‑2 with a high‑dose inactivated influenza component, aimed at protecting adults aged 60 and older.

• Matrix‑M adjuvant enhanced immune responses
• Variant‑specific SARS‑CoV‑2 immunity assessment
• Broad‑coverage protection across multiple influenza strains

Based in Naunhof, Germany, the two‑investigator team conducts these vaccine trials to ensure comparable immune responses to existing standards, supporting public health goals for senior populations.